TheraRadar
← Back
Data updated: Mar 29, 2026

MSN

OncologyCardiovascularNeurology
Generics

MSN is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology. Key products include OLUMIANT.

2017
Since
90
Drugs
-
Trials
962
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 33%
12 drugs
Cardiovascular 28%
10 drugs
Neurology 17%
6 drugs
Respiratory 11%
4 drugs
Gastroenterology 11%
4 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...